"MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis" by Andrej Spec

Article

MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis

Journal of Antimicrobial Chemotherapy (2019)

Andrej Spec, Washington University in St. Louis
John Pullman, Mercury Street Medical, Butte, MT, USA
George R Thompson, University of California, Davis
William G Powderly, Washington University in St. Louis
Ellis H Tobin, Albany Medical College
Jose Vazquez, Georgia Regents University
Stephen A Wring, Scynexis, Inc., Jersey City, NJ, USA
David Angulo, Scynexis, Inc., Jersey City, NJ, USA
Silvia Helou, Scynexis, Inc., Jersey City, NJ, USA
Peter G Pappas, University of Alabama at Birmingham
Jose Vasquez
Luis Ostrosky-Zeichner
Thomas Patterson
Barbara Alexander
Helen Boucher
Peter Pappas, University of Alabama at Birmingham
Robert Betts
Mindy Schuster
Shmuel Shoham
Sanjay Revankar
David Mushatt
Roger Bedimo
Alison Freifeld
Minh Hong Nguyen
Eleftherios Mylonakis
Daniel Kett
Annette Reboli
Thomas Walsh
Stephanie Pouch
Nikolaos Almyroudis
David Andes
Susan Hadley
Michelle Barron
Katheen Mullane
Loren Miller

Link

Disciplines

Publication Date

October 1, 2019

DOI

10.1093/jac/dkz277

Citation Information

Andrej Spec, John Pullman, George R Thompson, William G Powderly, et al.. "MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis" Journal of Antimicrobial Chemotherapy Vol. 74 Iss. 10 (2019) p. 3056 - 3062
Available at: http://works.bepress.com/annette-reboli/75/